Navigation Links
Anti-HAV antibodies in beta-thalassemia
Date:4/30/2008

Thalassemic patients were found to present a higher prevalence of anti-HAV IgG antibodies than matched healthy subjects from the same geographic area. This finding is difficult to explain, but it may be attributed to the higher vulnerability of thalassemics to HAV infection and to passive transfer of anti-HAV antibodies by blood transfusion.

This study, performed by a team led by Associate Professor C Labropoulou-Karatza and Dr D Siagris, is described in a research article to be published on March 14, 2008, in the World Journal of Gastroenterology.

In Greece, the lack of Hepatitis A epidemics since the early 1980s and the improvement of socioeconomic and hygienic conditions over the last decade seem to have contributed to a decline in prevalence of anti-HAV antibodies. However, the authors observed that the majority of their beta-thalassemia patients were anti-HAV-IgG-positive.

In the view of the authors, the findings of this study are in contradiction with those of previous studies which showed a lower prevalence of anti-HAV antibodies in thalassemic patients.

In order to further reduce the incidence of liver infections in multitransfused thalassemic patients, the authors recommend active immunization for HAV in that population.

In the view of the reviewers, the strength of this study is surely due to the dimension of the population and the long history of the patients (10 years).

Further research, including testing the prevalence of anti-HAV antibodies in family members of thalassemia patients and in the frozen aliquots of donors plasma, would confirm these findings.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring
4. Autoantibodies and neuropsychiatric events in lupus
5. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
6. Gene variant linked to moderated symptoms of beta-thalassemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing ... by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the ... 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: